Vitro Biopharma, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Oct 31, 2025	FY2024 12 months to Oct 31, 2024	FY2023 12 months to Oct 31, 2023	FY2015 12 months to Oct 31, 2015	FY2014 12 months to Oct 31, 2014
Product sales
Revenues
Product
Product Sales Related Parties
Consulting Revenue
Total revenues
Cost of Goods Sold
Gross Profit
Professional services income
Operating Costs and Expenses:
Selling, General and Administrative
Total operating costs and expenses
Research and Development
Write-off of Offering Costs
Impairment Expense
Loss From Operations

Other Expense:
Income (loss) before income taxes
Provision for income taxes (Note C)
Net (loss)
Interest Expense
Other Project Income, Net
Gain on Forgiveness of Debt
Gain (Loss) on Extinguishment of Debt
Unrealized Gain on Derivative/Warrant Liability
Net Loss
Net Income (Loss) per common share, basic and diluted
Shares used in computing Net Income (Loss) per common share: Basic and diluted

Cumulative Series A-1 Convertible Preferred Stock Dividend Requirement
Net Loss Available to Common Stockholders
Net Loss per Common Share, Basic
Net Loss per Common Share, Diluted
Shares Used in Computing Net Loss per Common Share, Basic
Shares Used in Computing Net Loss per Common Share, Diluted

Comments